Clinical Trial

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

Study acronym: Breast53
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and effectiveness of adjuvant chemoradiation therapy in high-risk breast cancer patients who had received neoadjuvant chemotherapy before their lumpectomy and/or mastectomy and were found to have residual disease. As well as examine the effects of this treatment combination on the immune system.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-03-10; most recent amendment 2025-04-15.
Status change: Not Yet Recruiting → Recruiting 2023-07-13
Trial Details
NCT Number NCT05288777
Lead Sponsor University of Virginia
Conditions Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Enrollment 45 participants
Start Date 2022-07-11
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-18